|Mr. Patrick J. McEnany||Co-Founder, Chairman, Chief Exec. Officer and Pres||496.56k||N/A||1947|
|Ms. Alicia Grande CPA, CMA||Chief Financial Officer, Chief Accounting Officer, VP and Treasurer||326.6k||N/A||1971|
|Dr. Steven R. Miller Ph.D.||Chief Operating Officer and Chief Scientific Officer||394.2k||N/A||1962|
|Dr. Gary Ingenito M.D., Ph.D.||Chief Medical Officer and Head of Regulatory Affairs||375.83k||N/A||1956|
|Mr. Brian Elsbernd||Sr. VP of Legal and Compliance||N/A||N/A||1964|
Catalyst Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases. Its product candidates include Firdapse, a proprietary form of amifampridine phosphate that has completed Phase III clinical trials for the treatment of patients with lambert-eaton myasthenic syndrome; is in Phase III clinical trial to treat congenital myasthenic syndromes; and is in Phase III clinical trial for the treatment of anti-MuSK antibody positive myasthenia gravis, as well as is in Phase II clinical trial for patients with spinal muscular atrophy type 3. The company is also developing CPP-115, a gamma-aminobutyric acid aminotransferase inhibitor for the treatment of refractory infantile spasms; and CPP-109, a vigabatrin tablet. It has license agreements with Northwestern University, New York University and the Feinstein Institute for Medical Research, and BioMarin Pharmaceutical Inc. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
Catalyst Pharmaceuticals, Inc.’s ISS Governance QualityScore as of April 1, 2018 is 6. The pillar scores are Audit: 1; Board: 6; Shareholder Rights: 8; Compensation: 5.